Skip to content

US · OKYO · BIOTECHNOLOGY

OKYO Pharma Limited (OKYO) intrinsic value and stock valuation

$1.07as of 2026-11-21 · Mkt cap 57.17M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

OKYO Pharma Limited DCF and intrinsic value

InvestorsCraft values OKYO with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from OKYO’s statements →

OKYO Pharma Limited Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology London, GL W1K 1NA okyopharma.com

How the business is doing

Fiscal 2012–2026, USD

Revenue
$0.00
20122026
Net income
-$-8.95M
20122026
Free cash flow
-$-5.94M
20122026
Total equity
$12.3M+18.3% 5y CAGRd
20122026

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2012–2026, USD
20262025202420232022
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-8.5M-$-7.19M-$-15.75M-$-13.09M-$-6.23M
Net income-$-8.95M-$-4.71M-$-16.83M-$-13.27M-$-5.43M
EPSd-$-239.56K-$-119.27K-$-573.62K-$-596.14K-$-360.56K
Operating cash flow-$-5.94M-$-1.81M-$-9.49M-$-7.7M-$-5.47M
Capital expenditure-$-10K-$0.00-$0.00-$-10K-$0.00
Free cash flow-$-5.94M-$-1.81M-$-9.49M-$-7.7M-$-5.47M
Total assets$21M$3.68M$1.54M$5.2M$4.3M
Total debt$0.00$0.00$0.00$2.22M$0.00
Net debt-$-14.59M-$-1.56M-$-830K-$-1.83M-$-2.7M
Total equity$12.3M-$-5.55M-$-5.88M-$-2.05M$2.95M
Cash and short-term investments$20.6M$1.56M$830K$4.05M$2.7M
Income statement
20262025202420232022
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$6.75M$10K
Gross profit$0.00-$0.00$0.00-$-6.75M-$-10K
Research and development expenses$1.81M$2.25M$8.24M$6.34M$1.61M
Selling, general and administrative expenses$0.00$4.93M$7.51M$6.75M$4.93M
Other expenses$6.69M$0.00$0.00-$-6.75M-$-320K
Operating expenses$8.5M$7.19M$15.8M$6.34M$6.22M
Cost and expenses$8.5M$7.19M$15.8M$13.1M$6.22M
Interest income$30K$10K$0.00$0.00$0.00
Interest expense$470K$880K$1.05M$100K$0.00
Depreciation and amortization$0.00$0.00$0.00$0.00$0.00
Ebitda-$-8.47M-$-7.08M-$-15.75M-$-13.08M-$-6.21M
Operating income-$-8.5M-$-7.19M-$-15.75M-$-13.09M-$-6.23M
Total other income/expenses, net-$-440K-$-780K-$-1.05M-$-200K$10K
Income before tax-$-8.94M-$-7.97M-$-16.8M-$-13.28M-$-6.22M
Income tax expense$10K-$-3.26M$20K-$-10K-$-790K
Net income-$-8.95M-$-4.71M-$-16.83M-$-13.27M-$-5.43M
Weighted average shares outstanding$37.4M$39.5M$29.3M$22.3M$15.1M
Weighted average diluted shares outstanding$37.4M$39.5M$29.3M$22.3M$15.1M
Balance sheet
20262025202420232022
Cash and short-term investments$20.6M$1.56M$830K$4.05M$2.7M
Net receivables$170K$1.89M$580K$980K$880K
Inventory$0.00$0.00$0.00$170K-$0.00
Total current assets$21M$3.68M$1.54M$5.2M$4.3M
Property, plant and equipment, net$10K$0.00$0.00$10K$10K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$10K$0.00$0.00$10K$10K
Total assets$21M$3.68M$1.54M$5.2M$4.3M
Accounts payable$7.14M$0.00$0.00$1.02M$520K
Short-term debt$0.00$0.00$0.00$2.22M$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$8.64M$9.23M$7.42M$7.26M$1.35M
Long-term debt$0.00$0.00$0.00$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$0.00$0.00$0.00$0.00$0.00
Capital lease obligations$0.00$0.00$0.00$0.00$0.00
Total liabilities$8.64M$9.23M$7.42M$7.26M$1.35M
Common stock$173.6M$0.00$0.00$0.00$124M
Retained earnings-$-151.97M-$-143.02M-$-142.52M-$-125.7M-$-112.43M
Accumulated other comprehensive income (loss)-$-12.13M-$-9.24M-$-6.47M-$-7.74M-$-11.01M
Total equity$12.3M-$-5.55M-$-5.88M-$-2.05M$2.95M
Total investments$6M$0.00$0.00$0.00$0.00
Total debt$0.00$0.00$0.00$2.22M$0.00
Net debt-$-14.59M-$-1.56M-$-830K-$-1.83M-$-2.7M
Cash flow statement
20262025202420232022
Net income-$-8.94M-$-7.97M-$-16.83M-$-13.28M-$-6.22M
Depreciation and amortization$0.00$0.00$0.00$0.00$0.00
Stock-based compensation$1.61M$730K$1.12M$0.00$1.72M
Change in working capital-$-630K$1.63M$2.67M$4.14M-$-1.02M
Accounts receivable$0.00$0.00$440K$170K$30K
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$360K$1.22M$2.8M$0.00-$-300K
Net cash provided by operating activities-$-5.94M-$-1.81M-$-9.49M-$-7.7M-$-5.47M
Investments in property, plant and equipment-$-10K-$0.00$0.00-$-10K-$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-6.01M-$0.00$0.00-$-10K-$0.00
Common stock issued$25M$1.71M$6.21M$7.32M$1.43M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$25M$2.66M$6.21M$9.32M$2.15M
Net change in cash$13M$730K-$-3.22M$1.34M-$-4.19M
Cash at end of period$14.6M$1.56M$830K$4.05M$2.7M
Operating cash flow-$-5.94M-$-1.81M-$-9.49M-$-7.7M-$-5.47M
Capital expenditure-$-10K-$0.00-$0.00-$-10K-$0.00
Free cash flow-$-5.94M-$-1.81M-$-9.49M-$-7.7M-$-5.47M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About OKYO Pharma Limited

        OKYO Pharma Limited is a biopharmaceutical firm operating at the preclinical stage, dedicated to developing innovative treatments for individuals in the United Kingdom experiencing inflammatory eye conditions and ocular discomfort. Its primary therapeutic candidate is OK-101, specifically designed to address dry eye disease. Additionally, the company is advancing OK-201, an experimental bovine adrenal medulla lipidated-peptide analogue, intended to treat neuropathic ocular pain. Established in 2007, OKYO Pharma Limited maintains its headquarters in London, UK.

        CEO
        Robert J. Dempsey
        Employees
        5
        Beta
        0.04

        Explore

        Frequently asked questions

        What is the intrinsic value of OKYO Pharma Limited (OKYO)?

        InvestorsCraft does not currently publish an intrinsic value for OKYO. How the IC value is calculated.

        Is OKYO undervalued?

        InvestorsCraft does not publish an undervaluation signal for OKYO at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.